1 citations
,
September 2025 in “Cureus” ChatGPT-5 can pass the endocrinology exam but isn't fully reliable for clinical decisions yet.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
February 2026 in “Cureus” Combination therapy is better for long-term control and outcomes in type 2 diabetes.
January 2025 in “Directory of Open access Books (OAPEN Foundation)” PCOS affects women's hormones and metabolism, but can be managed with lifestyle changes and treatments.
December 2024 in “African Journal of Biomedical Research” Combining lifestyle changes and medication is most effective for managing PCOS symptoms.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Tailored medication preparation and ongoing education are crucial for effective treatments.
October 2024 in “Irish Journal of Medical Science (1971 -)” Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.
3 citations
,
December 2023 in “International Journal of Nanomedicine” Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.
May 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient education and personalized care.
Vaccination is crucial for public health, but anti-vaccine movements are a concern.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
Individualized treatments may help manage Dercum's disease symptoms.
December 2023 in “PubMed” Metformin and liraglutide improved symptoms of HAIR-AN syndrome in a child.
August 2025 in “Journal of the American Academy of Dermatology”
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
7 citations
,
September 2019 in “European Journal of Case Reports in Internal Medicine” Linagliptin may cause hair loss and skin blisters.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
1 citations
,
January 2025 in “ARC Journal of Dermatology” 5 citations
,
August 2024 in “Cureus” GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
9 citations
,
July 2017 in “Case Reports in Dermatology” Combination therapy helped patient with advanced Hidradenitis Suppurativa achieve remission.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.